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  32	  
Abstract  33	  
Context Corticosteroid injection and physiotherapy, common treatments for lateral 34	  
epicondylalgia, are frequently combined in clinical practice. Study of their combined efficacy 35	  
is lacking. 36	  
Objective To investigate the effectiveness of corticosteroid injection, multimodal 37	  
physiotherapy, or both, in patients with unilateral lateral epicondylalgia. 38	  
Design, Setting and Patients A 2x2 factorial, randomized, injection blinded, placebo 39	  
controlled trial was conducted at a single university research centre and 16 primary care 40	  
settings in Brisbane, Australia. 165 patients with unilateral lateral epicondylalgia of greater 41	  
than six weeks duration were enrolled between July 2008 and May 2010. One year follow-up 42	  
was completed in May 2011. 43	  
Intervention Corticosteroid injection (n=43), placebo injection (n=41), corticosteroid 44	  
injection plus physiotherapy (n=40) or placebo injection plus physiotherapy (n=41). 45	  
Main outcome measures Primary endpoint/outcomes were one year global rating of change 46	  
scores of complete recovery/much improvement, as well as one year recurrence, defined as 47	  
global rating of change scores of complete recovery/much improvement at 4 or 8 weeks, but 48	  
not later, analysed on an intention to treat basis (P<0.01). Secondary time points included 4 49	  
and 26 weeks. 50	  
Results Compared to placebo injection, corticosteroid injection resulted in lower complete 51	  
recovery/much improvement at one year (83% v 96%, RR 0.86 (99% CI 0.75 to 0.99), 52	  
P=0.01) and greater recurrence (54% v 12%, RR 0.23 (0.10 to 0.51), P<0.001). 53	  
Physiotherapy and no-physiotherapy groups did not differ on one year ratings of complete 54	  
recovery/much improvement (91% v 88%, RR 1.04 (0.90 to 1.19),  P=0.56) or recurrence 55	  
(29% v 38%, RR 1.31 (0.73 to 2.35), P=0.25). A similar pattern was found at 26 weeks, with 56	  
lower complete recovery/much improvement following corticosteroid than placebo injection 57	  
(55% v 85%, RR 0.79 (0.62 to 0.99), P<0.001) and no difference between physiotherapy and 58	  
no-physiotherapy (71% v 69%, RR 1.22 (0.97 to 1.53), P=0.84). At four weeks, there was an 59	  
interaction between corticosteroid injection and physiotherapy (P=0.01) whereby in placebo 60	  
injected patients physiotherapy resulted in greater complete recovery/much improvement 61	  
than no-physiotherapy (39% v 10%, RR 4.00 (1.07 to 15.0), P=0.004), but not in 62	  
corticosteroid injected patients (68% v 71%, RR 0.95 (0.65 to 1.38), P=0.57). 63	  
Conclusions Among patients with chronic unilateral epicondylalgia, after one year the use of 64	  
corticosteroid injection compared with placebo resulted in worse clinical outcomes, and 65	  
physiotherapy did not result in any significant difference. 66	  
Trial registration Australian Clinical Trials Registry (ACTRN12609000051246)  67	  
Introduction   68	  
 69	  
There are increasing calls for medical practitioners to desist from using corticosteroid 70	  
injections to treat lateral epicondylalgia,1,2 which is likely based on evidence of long term 71	  
inefficacy3-5 and high recurrence.3,6 In a recent randomized controlled trial with one year 72	  
follow-up, recurrence was evident in 72% of corticosteroid injected patients, compared to 8% 73	  
following physiotherapy.3 To overcome the poor long term outcomes of injections, clinicians 74	  
often recommend combining corticosteroid injection and physiotherapy interventions. This 75	  
has only been evaluated in two small studies.7,8 One reported no benefit at six months of 76	  
corticosteroid injection when added to ice massage and physiotherapy prescribed exercise.7 77	  
The other found no significant effect of a progressive graduated exercise program when 78	  
added to corticosteroid injection, however this study was underpowered, reported a high 79	  
drop-out rate and did not assess outcomes beyond seven weeks.8 The long term effects of a 80	  
combination of corticosteroid injection and physiotherapy are not known. 81	  
In contrast to the poor long term outcomes, corticosteroid injections produce substantial pain 82	  
relief in the short term,3,5,9 which is somewhat perplexing given their anti-inflammatory mode 83	  
of action juxtaposed against the lack of inflammatory markers in tendinopathy.10-12 A 84	  
plausible explanation is that these injections are associated with strong placebo effects.13 A 85	  
recent systematic review found significant heterogeneity for studies comparing corticosteroid 86	  
with placebo injection, with three out of four studies showing no difference,14 though the use 87	  
of lidocaine and bupivicaine injections as placebo comparators might have exerted a 88	  
therapeutic effect.13 There is a critical need to evaluate the efficacy of corticosteroid injection 89	  
compared to a placebo injection of normal saline. 90	  
The primary objectives of this study were two-fold: to evaluate at one year the clinical 91	  
efficacy of (1) corticosteroid injection compared to placebo injection, and (2) physiotherapy 92	  
compared to no-physiotherapy in patients with unilateral lateral epicondylalgia. The primary 93	  
outcomes were (a) patient rated global rating of change scores of complete recovery or much 94	  
improvement, and (b) recurrence, defined as complete recovery/much improvement at 4 or 8 95	  
weeks, but not 8, 26 or 52 weeks. 96	  
 97	  
Methods 98	  
Study design  99	  
A randomized control trial with 2x2 factorial design and one year follow-up was performed 100	  
in a community setting in Brisbane, Australia, as per our previously published protocol.13 101	  
Injection and physiotherapy factors were combined to constitute four treatment groups (1) 102	  
corticosteroid injection; (2) placebo injection; (3) corticosteroid injection plus multimodal 103	  
physiotherapy; (4) placebo injection plus multimodal physiotherapy. This trial was registered 104	  
with the Australian Clinical Trials Registry (ACTRN12609000051246) and approved by the 105	  
Medical Research Ethics Committee (University of Queensland). 106	  
 107	  
Patients 108	  
Adults aged 18 years or over with unilateral lateral epicondylalgia of duration longer than six 109	  
weeks, who responded to public advertisement between August 2008 and May 2010, were 110	  
invited to participate. Inclusion criteria were pain over the lateral humeral epicondyle of 111	  
severity greater than 30 on a 100mm visual analogue scale (VAS), provoked by at least two 112	  
of: gripping, palpation, resisted wrist or middle finger extension or stretching of forearm 113	  
extensor muscles with reduced pain-free grip. Exclusion criteria were injection (preceding six 114	  
months); course of physiotherapy (preceding three months); concomitant neck or other arm 115	  
pain necessitating treatment or preventing participation in usual work or recreational 116	  
activities (preceding six months); symptoms suggesting radicular, neurological or systemic 117	  
arthritic conditions; pregnancy; breastfeeding; or contraindication to injection. Eligibility was 118	  
determined by telephone interview and physical examination by one researcher and 119	  
confirmed by a second researcher. 120	  
 121	  
Randomization  122	  
Following written informed consent, randomization was performed by concealed allocation 123	  
using a computer-generated schedule, developed by the Queensland Clinical Trials Centre, an 124	  
independent offsite organisation. Randomization was stratified according to pain severity 125	  
greater or less than 57.5mm on a 100mm VAS, based on the mean score from a previous 126	  
study.3 A research assistant not involved in data collection or analysis, administered the 127	  
randomization schedule and arranged all study appointments. 128	  
 129	  
Blinding 130	  
The researcher who assessed outcomes and performed intention to treat analysis was blinded 131	  
to both injection and physiotherapy assignment. Patients were masked to injection content, 132	  
but not to physiotherapy due to its nature. To evaluate the success of blinding, patients were 133	  
asked at eight weeks whether they were confident of which injection they received, and those 134	  
who responded yes were asked to nominate the injection. The outcome assessor guessed both 135	  




Patients received a single injection of either placebo (0.5ml, 0.9% isotonic saline) or 140	  
corticosteroid and local anaesthetic medication (1ml, 10mg/ml Triamcinolone Acetonide, 141	  
Kencort A10, with 1ml, 1% Lignocaine) by one of five medical practitioners within 10 days 142	  
of randomization. The injection was applied to the site of greatest palpable tenderness at the 143	  
common extensor origin. All patients received standardized advice to avoid activities that 144	  
caused or provoked pain and to rest from strenuous activity for two weeks post-injection. 145	  
Following this gradual return to normal activities was encouraged, even if substantial initial 146	  
relief was obtained, to minimise potential recurrence. Patients could use analgesic or anti-147	  
inflammatory medication, heat/cold or braces as needed, but were discouraged from seeking 148	  
treatments other than those assigned.  149	  
 150	  
Physiotherapy 151	  
Physiotherapy groups underwent eight, thirty-minute sessions of treatment over an eight 152	  
week period, with the first session scheduled prior to the injection. Eleven physiotherapy 153	  
practitioners with post-graduate qualification underwent two hours of training (by BKC and 154	  
BV) to standardize the treatment according to a previously published protocol,13 which 155	  
comprised local elbow manual therapy and exercise. To individualise treatment, practitioners 156	  
chose manual therapy and exercises from the protocol and progressed the program based on 157	  
the patients’ capabilities to allow for optimal exercise volume and load setting without 158	  
exacerbating pain. The specific elbow manipulation (mobilisation with movement) 159	  
techniques were applied in combination with gripping as described by Vicenzino.15 The 160	  
comprehensive exercise program included twice daily sensorimotor retraining of gripping and 161	  
concentric and eccentric exercise to progressively load the wrist extensors using resistive 162	  
theraband. The home program was regularly reviewed and exercise diaries were monitored to 163	  
facilitate program adherence. 164	  
 165	  
Outcome measures 166	  
Patients estimated at each trial visit (4,8,12,26,52 weeks) their global rating of change since 167	  
commencing the study using a 6-point Likert scale, ranging from “complete recovery” to 168	  
“much worse”.3,13 A priori primary endpoint/outcomes were one year global rating of change 169	  
scores of complete recovery/ much improvement, as well as one year recurrence, defined as 170	  
global rating of change scores of complete recovery/much improvement  at 4 or 8 weeks, but 171	  
not 8, 26 or 52 weeks. 172	  
 173	  
Secondary time points/outcomes were: global rating of change scores of complete 174	  
recovery/much improvement (4 and 26 weeks); severity of current resting pain and worst 175	  
pain over the preceding week (100mm VAS); a condition-specific, validated questionnaire of 176	  
pain and disability (Patient-rated Tennis Elbow Evaluation, PRTEE, ranging from 0 to 100, 177	  
where 100 represents worst imaginable pain with a very significant functional disability)16,17; 178	  
health-related quality of life (EuroQol EQ-5D, ranging from 0 to 1, where 1 represents 179	  
perfect health)18 (4, 26 and 52 weeks); use of analgesic or anti-inflammatory medication or 180	  
other non-allocated treatments and adverse events. Minimum clinically important changes in 181	  
pain and disability (as measured using the PRTEE) of 37% of baseline scores are reported for 182	  
clinical significance defined as ‘much better’ or ‘completely recovered’ in patients with 183	  
lateral epicondylalgia.19  184	  
 185	  
Statistical analysis 186	  
The primary hypotheses of this 2x2 factorial design study were that after one year, clinical 187	  
outcomes would be worse in patients receiving injection of corticosteroid (than placebo), 188	  
while better in those receiving physiotherapy (than no-physiotherapy). At the outset of the 189	  
trial, we did not anticipate an interaction between the two interventions.20 A total sample size 190	  
of 120 patients (α=0.05, β=0.2) was initially estimated to detect a clinically meaningful 191	  
difference of 25% for the two factorial (at-margin) comparisons (corticosteroid v placebo; 192	  
physiotherapy v no-physiotherapy) for all primary hypotheses based on previous studies.3,5 At 193	  
a trial steering committee meeting (before recruitment ended), however, we decided to inflate 194	  
the sample size to 165 to permit adequate power for the following a priori pairwise 195	  
comparisons:21 corticosteroid injection v placebo injection alone; corticosteroid injection plus 196	  
physiotherapy v placebo injection plus physiotherapy; placebo injection v placebo injection 197	  
plus physiotherapy; and corticosteroid injection v corticosteroid injection plus physiotherapy, 198	  
as well as account for loss to follow-up. No interim analyses were performed during the study 199	  
period. 200	  
 201	  
Statistical analysis was done on a blinded intention to treat basis using SPSS version 20.0 202	  
(IBM, Somers, New York, USA) with a priori P<0.01 (two-sided) significance because of 203	  
multiple comparisons. The effects of injection and physiotherapy on complete recovery/much 204	  
improvement and recurrence were analysed using binary logistic regression, including as a 205	  
covariate baseline worst pain (VAS), which is a recognised prognostic factor.22 We 206	  
investigated for interactions between injection and physiotherapy factors and interpreted 207	  
results of pairwise comparisons when a significant interaction was found.  We calculated the 208	  
relative risk (RR, 99% CI) of complete recovery/much improvement by dividing the 209	  
corticosteroid (or physiotherapy) risk by the placebo (or no-physiotherapy) risk. We also 210	  
calculated the RR of recurrence by dividing the placebo (or no-physiotherapy) risk by the 211	  
corticosteroid (or physiotherapy) risk. Numbers needed to treat (NNT, 99% CI) were 212	  
generated as a meaningful indicator of treatment efficacy for practitioners.23 Continuous 213	  
outcomes were analysed using linear regression, including baseline values of the dependent 214	  
variable as a covariate. Main effects or pairwise comparisons (where significant interaction)21 215	  
were expressed as standardised mean differences (SMD, 99% CI), calculated using RevMan 216	  
statistical software version 5.0.24 A beneficial effect of corticosteroid and physiotherapy were 217	  
defined as RR>1, or SMD and NNT >0, while a harmful effect of corticosteroid and 218	  
physiotherapy were defined as RR<1, or SMD and NNT <0. A SMD 0.2- 0.5 was defined as 219	  
a small effect, SMD 0.5-0.8 as a medium effect and greater than 0.8 as a large effect.25 220	  
 221	  
Results 222	  
165 patients were enrolled between July 2008 and May 2010. Figure 1 summarizes patient 223	  
recruitment, participation and attrition. The most common reasons for exclusion of patients 224	  
with suspected lateral epicondylalgia were recent treatment (27%), declined to participate 225	  
(21%), concomitant neck or shoulder pain (17%), bilateral elbow pain (15%) or resolution of 226	  
lateral epicondylalgia (8%). Elbow surgery, a history of repeated corticosteroid injection, 227	  
neurological symptoms and other contraindications made up the remaining 12% of excluded 228	  
patients. The trial was completed in May 2011, with 163 patients (99%) completing primary 229	  
outcomes at one year and two unrelated deaths from cancer recorded. Due to the small 230	  
proportion of missing values (n=3, 2%) we decided not to do any imputation. The omitted 231	  
cases were similar in baseline characteristics to the total sample. No significant differences in 232	  
baseline characteristics were found between the four groups (Table 1). The median duration 233	  
of lateral epicondylalgia was 16 weeks (range six weeks to four years) with 76% presenting 234	  
with their first episode.  235	  
 236	  
Four patients did not receive the allocated injection (1 placebo, 3 corticosteroid) due to non-237	  
attendance (n=2, 1%) or alternative medical advice (n=2, 1%). The mean (SD) number of 238	  
physiotherapy sessions attended was 7.5 (1.9). Seven patients (9%) completed less than four 239	  
physiotherapy sessions, due to non-attendance, moving interstate or recovery. Seventy 240	  
percent of patients were compliant with their home exercise program on at least five out of 241	  
seven weeks. Two (2%) corticosteroid injected patients had an additional corticosteroid 242	  
injection, while seven (8%) patients not allocated to physiotherapy, pursued physiotherapy 243	  
external to the trial. Injection and physiotherapy allocation was correctly guessed by the 244	  
outcome assessor in 53% (20/38) of cases receiving placebo injection only, 39% (16/41) of 245	  
placebo injection plus physiotherapy, 44% (18/41) of corticosteroid injection only, 246	  
44%(15/38) of corticosteroid injection plus physiotherapy. Thirty-seven percent (50/137) of 247	  
patients stated they were confident of which injection they received, with correct responses 248	  
identified by 71% (20/28) of corticosteroid injected patients and 73% (16/22) of placebo 249	  
injected patients. No differences were found between interventions. 250	  
 251	  
Descriptive statistics for the four randomized groups for a priori time points (4, 26 and 52 252	  
weeks) are presented in Table 2, while additional data is provided online (eTable 1). Primary 253	  
outcomes 254	  
There was no interaction between injection and physiotherapy at one year (P=0.99). Our first 255	  
hypothesis was supported, with corticosteroid injection demonstrating lower complete 256	  
recovery/much improvement (68/82 (83%) v 78/81 (96%), RR 0.86 (99% CI 0.75 to 0.99), 257	  
NNT -7.5 (99% CI -150.9 to -3.7), P=0.01) and greater recurrence (44/81 (54%) v 10/81 258	  
(12%), RR 0.23 (0.10 to 0.51), NNT -2.4 (-4.3 to -1.8), P<0.001) compared to placebo 259	  
injection at one year (Figure 2A). The second hypothesis was not supported, with no 260	  
differences between physiotherapy and no-physiotherapy for complete recovery/much 261	  
improvement (73/80 (91%) v 73/83 (88%), RR 1.04 (0.90 to 1.19), P=0.56) or recurrence 262	  
(23/80 (29%) v 31/82 (38%), RR 1.31 (0.73 to 2.35), P=0.25) (Figure 2B).  263	  
 264	  
Secondary time points/ outcomes 265	  
Four weeks 266	  
At 4 weeks, there was a significant interaction between injection and physiotherapy for 267	  
complete recovery/much improvement (P=0.01; Figure 2), as well as worst pain (P<0.001), 268	  
pain and disability (P<0.001) and quality of life (P =0.004) (Figure 3). In the absence of 269	  
physiotherapy, complete recovery/much improvement was greater following corticosteroid 270	  
than placebo injection (RR 7.32 (99% CI 2.1 to 25.5), NNT 1.6 (99% CI 1.3 to 2.9), 271	  
P<0.001), and was associated with large benefits for all secondary outcomes- worst pain 272	  
(SMD 1.77 (99% CI 1.09 to 2.44), P<0.001), resting pain (SMD 0.87 (0.28 to 1.46); 273	  
P<0.001), pain and disability (SMD 1.81 (1.13 to 2.48), P<0.001) and quality of life (SMD 274	  
1.14 (0.53 to 1.76), P<0.001). This was not the case for most outcomes when physiotherapy 275	  
was present, with no differences in complete recovery/much improvement (RR 1.73 (0.97 to 276	  
3.08), P=0.02), worst pain (SMD 0.51 (-0.08 to 1.09), P=0.03), resting pain (SMD 0.21 (-277	  
0.36 to 0.79), P=0.29) or quality of life (SMD 0.30 (-0.27 to 0.88), P=0.08), but there was a 278	  
medium-sized benefit of corticosteroid injection on pain and disability (SMD 0.63 (0.04 to 279	  
1.22), P<0.001). In corticosteroid injected patients, physiotherapy had no effect on any 280	  
outcome (complete recovery/much improvement RR 0.95 (0.65 to 1.38), P=0.57; worst pain 281	  
SMD -0.38 (-0.96 to 0.19), P=0.10; resting pain SMD -0.05 (-0.62 to 0.52), P=0.91); pain 282	  
and disability SMD -0.40 (-0.97 to 0.18), P=0.12; quality of life SMD -0.30 (-0.88 to 0.27), 283	  
P=0.29). This contrasted with placebo injected patients, in which physiotherapy resulted in 284	  
greater complete recovery/much improvement (RR 4.00 (1.07 to 15.0), NNT 3.4 (2.0 to 285	  
21.4), P=0.004), along with medium-sized benefits of worst pain (SMD 0.88 (0.29 to 1.48), 286	  
P<0.001), resting pain (SMD 0.60 (0.02 to 1.19), P=0.01) and pain and disability (SMD 0.77 287	  
(0.18 to 1.37), P=0.001). 288	  
 289	  
26 weeks 290	  
There were no significant interaction effects at 26 weeks. Corticosteroid injection 291	  
demonstrated lower complete recovery/much improvement than placebo injection (45/82 292	  
(55%) v 69/81 (85%), RR 0.79 (0.62 to 0.99), NNT -5.5 (-123.1 to -2.9), P<0.001), supported 293	  
by medium-sized deficits on all other outcomes - worst pain (SMD -0.77 (-1.19 to -0.35), 294	  
P<0.001), resting pain (SMD -0.61 (-1.02 to -0.19), P<0.001), pain and disability (SMD -295	  
0.76 (-1.18 to -0.34), P<0.001) and quality of life (SMD -0.55 (-0.97 to -0.14), P=0.004). 296	  
Physiotherapy demonstrated no effect on any outcome (complete recovery/much 297	  
improvement 57/80 v 57/83, RR 1.22 (0.97 to 1.53), P=0.84; worst pain SMD 0.04 (-0.36 to 298	  
0.44), P=0.79; resting pain SMD 0.05 (-0.35 to 0.46), P=0.74; pain and disability SMD 0.07 299	  
(-0.33 to 0.48), P=0.25; quality of life SMD 0.33 (-0.08 to 0.74), P=0.13). 300	  
 301	  
52 weeks 302	  
There were no significant interaction effects at 52 weeks. Consistent with primary outcomes, 303	  
worst pain remained significantly higher for corticosteroid than placebo injection at one year, 304	  
although differences were small (SMD -0.44 (-0.85 to -0.03), P=0.005). No differences were 305	  
found between injection types for resting pain (SMD -0.17 (-0.58 to 0.23), P=0.29), pain and 306	  
disability (SMD -0.36 (-0.76 to 0.05), P=0.02) or quality of life (SMD -0.22 (-0.63 to 0.18), 307	  
P=0.21). Physiotherapy demonstrated no effect on any outcome (complete recovery/much 308	  
improvement 73/80 v 73/83, RR 1.04 (0.90 to 1.19), P=0.56; worst pain SMD -0.07 (-0.47 to 309	  
0.34), P=0.66; resting pain SMD -0.07 (-0.47 to 0.34), P=0.64; pain and disability SMD 0.05 310	  
(-0.36 to 0.45), P=0.51; quality of life SMD 0.00 (-0.40 to 0.40), P=0.70). 311	  
 312	  
Use of analgesic or anti-inflammatory medication (Table 2) did not differ between injection 313	  
of corticosteroid or placebo (26/83 (31%) v 23/82 (28%); P=0.57), while was less frequently 314	  
used by patients allocated to physiotherapy than those not allocated to physiotherapy (16/81 315	  
(20%) v 33/84 (39%), NNT 5.1 (2.8 to 84.8), P=0.008). Non-protocol medical consultations 316	  
did not differ between injection (15/83 (8%) v 8/82 (10%), P=0.13) or physiotherapy (7/81 317	  
(9%) v 16/84 (19%), P=0.06) factors. 318	  
 319	  
Adverse events reported in this study were minor, transient and not significantly different 320	  
between injection or physiotherapy factors (Table 2). Skin depigmentation (4/83, 5%) and 321	  
subcutaneous atrophy (3/83, 4%) occurred exclusively in patients receiving corticosteroid 322	  
injection, showed a delayed onset (evident on examinations at 8 or 12 weeks) and was 323	  
resolved by 26 weeks.  324	  
 325	  
Comment 326	  
In this placebo-controlled study, a single, blinded injection of corticosteroid medication was 327	  
associated with poorer long term outcomes and higher recurrence rates one year following 328	  
injection in patients with lateral epicondylalgia. Eight weeks of multimodal physiotherapy, 329	  
comprising elbow mobilisation with movement and exercise, did not optimise long term 330	  
outcomes, but was beneficial in the short term in the absence of corticosteroid injection. 331	  
Significantly fewer patients receiving physiotherapy consumed analgesic or anti-332	  
inflammatory medication. 333	  
 334	  
A recent systematic review (search date March 2010)4 reported that it was not possible to 335	  
make a definitive declaration regarding the efficacy of corticosteroid injection beyond 336	  
placebo, largely due to significant heterogeneity for studies making this comparison. Our 337	  
current study provides evidence of the short term effectiveness of corticosteroid injection 338	  
compared to placebo injection, when injected alone. Notwithstanding this, differences in 339	  
complete recovery/much improvement were not significant when patients also received 340	  
physiotherapy, a finding echoed by Newcomer et al. in a study of lateral epicondylalgia of 341	  
less than six weeks duration.7 This evidence does not support the clinical opinion that 342	  
corticosteroid injection be used to facilitate active rehabilitation.  343	  
 344	  
Results were reversed at six months, with corticosteroid injection displaying moderate to 345	  
large inferior effects consistently across measures of complete recovery/much improvement, 346	  
pain, disability and quality of life. At one year, most (90%) patients reported complete 347	  
recovery/much improvement, which reflects the natural history of the condition.3,5,9 However, 348	  
significantly fewer patients reported being completely recovered or much improved, and 349	  
worst pain levels remained higher one year following corticosteroid injection. Furthermore, 350	  
over half of all patients treated with a single corticosteroid injection experienced a recurrence, 351	  
substantially greater than placebo. In clinical terms, this represented a NNT of 2.4, i.e., for 352	  
every two or three people treated with corticosteroid injection (in comparison to placebo), 353	  
one person experienced recurrence over the year. Whilst high recurrence rates following 354	  
corticosteroid injection have been previously reported,3,5 this study provides evidence that it 355	  
may be the effect of the medication and not merely a manifestation of the disease or the 356	  
injection.  357	  
 358	  
The biological basis for the clinical effect of corticosteroids in lateral epicondylalgia is still 359	  
largely unknown. Corticosteroids are potent in suppressing inflammation,26 but the prevailing 360	  
opinion is that no histological evidence of acute inflammation has been documented,11,12,27,28 361	  
although inflammatory cells have been detected by newer studies using 362	  
immunohistochemistry.29,30 The early response of corticosteroids may be due to an analgesic 363	  
effect on the neuropeptides, calcitonin gene-related peptide and substance P, which are 364	  
increased in tendinopathy.28 Recurrence may occur as corticosteroids do not address key 365	  
features of tendinopathy, which is traditionally thought to be associated with overuse or 366	  
cumulative trauma weakening collagen cross-linking and the non-collagenous matrix and 367	  
vascular elements of tendon.28 Indeed, the medication might be deleterious to the tendon 368	  
through an effect on fibroblasts’ role in collagen and extracellular matrix protein 369	  
production.26 Others have proposed that the poor long term clinical effect of corticosteroid 370	  
injection might be related to the immediate pain relief and conceivable excessive or 371	  
inappropriate early activity.3,28{Fredberg, 2008 #64;Bisset, 2006 #1} 372	  
 373	  
Contrary to our hypothesis and to a generally held clinical view,2 we found that multimodal 374	  
physiotherapy provided no beneficial long term effect on complete recovery/much 375	  
improvement, recurrence, pain, disability or quality of life, thereby not supporting the 376	  
hypothesis that the combined approach is superior. However, physiotherapy should not be 377	  
dismissed altogether, because in the absence of corticosteroid, it provided short term benefit 378	  
across all outcomes, as well as the lowest recurrence rates (4.9%) and 100% complete 379	  
recovery/much improvement at one year. At four weeks, the magnitude of improvement on 380	  
PRTEE, a validated, condition-specific measure of pain and disability, exceeded previously 381	  
reported minimum clinically important differences19 for patients receiving corticosteroid 382	  
injection and/or physiotherapy, but not those receiving placebo injection alone. A previous 383	  
study showed a similar multimodal physiotherapy program was superior to wait and see in 384	  
the short term.3  385	  
 386	  
The strengths of this study lie in the high retention (99.8%) of patients after extended follow-387	  
up and consistency of findings across validated condition-specific and generic outcomes. It 388	  
also has limitations. First, results may not be generalized to other clinical contexts where 389	  
treatments are reserved for specific individuals or combined in a different sequence or 390	  
manner, for example; injection of patients who have not recovered following a period of wait 391	  
and see or physiotherapy; or treatment with physiotherapy in patients with poor late outcomes 392	  
following injection. Secondly, it is not uncommon for lateral epicondylalgia to present 393	  
bilaterally or be associated with concomitant symptoms of the neck or upper limb.22 We 394	  
limited our study population to patients with unilateral lateral epicondylalgia, without 395	  
significant neck or other upper limb symptoms, which needs to be considered in applying our 396	  
findings to clinical practice. In addition, we excluded patients who had received recent 397	  
treatment or repeated corticosteroid injection as these may have biased findings. Excluding 398	  
prior corticosteroid injection suggests that our findings are best case scenario in terms of its 399	  
long term outcomes.	  A previous study found a poorer long term effect of repeated 400	  
corticosteroid injection (mean 4.3 injections in 18 months) on reduction of pain than 401	  
treatment with one injection.31 It should be acknowledged that while the assessor was blinded 402	  
to treatments received by the patients, the lack of patient and therapist blinding to 403	  
physiotherapy might have biased estimates of the benefit of physiotherapy, the mitigation of 404	  
which should be considered in future study designs.31 405	  
  406	  
 407	  
In conclusion, among patients with chronic unilateral epicondylalgia, one year after 408	  
corticosteroid injection there was a worse clinical outcome compared with placebo, despite 409	  
its short term benefits. Physiotherapy did not result in any significant 1-year difference.  410	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434	  
Figure 1: Study flow diagram 435	  
Patients were lost to follow-up if they did not provide global rating of change scores. Patients 436	  
who discontinued treatment had the opportunity to provide follow-up data.  437	  
 438	  
Figure 2: Relative risk (RR) of complete recovery or much improvement and 439	  
recurrence and 99% confidence interval (CI) for (A) corticosteroid injection relative to 440	  
placebo injection and (B) for addition of physiotherapy relative to no-physiotherapy.  441	  
Effect statistics are for the total population (diamond or triangle) or in the case of significant 442	  
interaction, for the following subgroups: no-physiotherapy (white circle), physiotherapy 443	  
(black circle), placebo injection (white square) or corticosteroid injection (black square). 444	  
Scores greater than one indicate outcomes in favour of the active intervention. 445	  
 446	  
Figure 3: Standardised mean differences (SMD) and 99% confidence interval (CI) for 447	  
(A) corticosteroid injection relative to placebo injection and (B) for addition of 448	  
physiotherapy relative to no-physiotherapy.  449	  
Effect statistics are for the total population (diamond or triangle) or in the case of significant 450	  
interaction, for the following subgroups: no-physiotherapy (white circle), physiotherapy 451	  
(black circle), placebo injection (white square) or corticosteroid injection (black square). 452	  
Positive scores indicate outcomes in favour of the active intervention. PRTEE: Patient-rated 453	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Patients, n 41 41 43 40 165 
Age (years) a 49·9 (7·4) 48·7 (7·7) 49·3 (8·9) 50·8 (8·5) 49·7 (8·1) 
Female b 17 (42%) 15 (37%) 16 (37%) 15 (38%) 63 (38%) 
Duration of symptoms (weeks) c 16 (8 to 32) 16 (8 to 24) 16 (10 to 27) 15 (10 to 26) 16 (10 to 26) 
Resting pain VAS (0-100) c 9 (0 to 22) 7 (0 to 11) 4.5 (0 to 18) 9 (0 to 15) 7.5 (0 to 15) 
Worst pain VAS (0-100) a 62·4 (19·8) 63·2 (18·0) 62·0 (20·3) 59·0 (15·8) 61·7 (18·5) 
Pain and disability (PRTEE: 0-100) a 41·6 (14·4) 36·4 (13·3) 42·0 (14·4) 38·1 (13·8) 39·5 (14·1) 
Quality of life (EQ-5ED: 0-1) a 0·74 (0·13) 0·74 (0·12) 0·68 (0·20) 0·74 (0·09) 0·73 (0·14) 
Data represents mean (SD)a, count (%)b, median (IQR)c. VAS = Visual analogue scale; 462	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Corticosteroid	  injection	  +	  
physiotherapy	  
Complete	  recovery	  or	  much	  improvement	  a	   	  	   	  	   	  	  
4	  weeks	   4/41,	  10%	  (3	  to	  28%)	   16/41,	  39%	  (22	  to	  59%)	   30/42,	  71%	  (52	  to	  85%)	   27/40,	  68%	  (47	  to	  83%)	  
26	  weeks	   33/40,	  83%	  (63	  to	  93%)	   36/41,	  89%	  (69	  to	  96%)	   24/43,	  56%	  (37	  to	  73%)	   21/39,	  54%	  (34	  to	  72%)	  
52	  weeks	   37/40,	  93%	  (75	  to	  98%)	   41/41,	  100%	  (86	  to	  100%)	   36/43,	  84%	  (65	  to	  93%)	   32/39,	  82%	  (62	  to	  93%)	  
Recurrence	  a,	  b	   	  	   	  	   	  	   	  	  
52	  weeks	   8/40,	  20%	  (9	  to	  40%)	   2/41,	  5%	  (1	  to	  21%)	   23/42,	  55%	  (36	  to	  73%)	   21/39,	  54%	  (34	  to	  72%)	  
Worst	  pain	  VAS	  c	   	  	   	  	   	  	   	  	  
4	  weeks	   56	  (30	  to	  70)	   35	  (15	  to	  45)	   5	  (0	  to	  22)	   1	  (10	  to	  25)	  
26	  weeks	   5	  (0	  to	  22)	   5	  (0	  to	  10)	   10	  (2	  to	  58)	   2	  (5.5	  to	  48.5)	  
52	  weeks	   0	  (0	  to	  5)	   0	  (0	  to	  3)	   0.5	  (0	  to	  10)	   5	  (0	  to	  18)	  
Resting	  pain	  	  VAS	  c	   	  	   	  	   	  	   	  	  
4	  weeks	   5	  (0	  to	  22)	   0	  (0	  to	  10)	   0	  (0	  to	  2)	   0	  (0	  to	  0)	  
26	  weeks	   0	  (0	  to	  0)	   0	  (0	  to	  0)	   0	  (0	  to	  14)	   0	  (0	  to	  8)	  
52	  weeks	   0	  (0	  to	  0)	   0	  (0	  to	  0)	   0	  (0	  to	  0)	   0	  (0	  to	  0)	  
Patient	  rated	  tennis	  elbow	  evaluation	  (PRTEE)	  c	   	  	   	  	  
4	  weeks	   31.8	  (20.5	  to	  43.8)	   22.5	  (9.5	  to	  28.5)	   6.5	  (2.5	  to	  12)	   7	  (2.5	  to	  16)	  
26	  weeks	   6.5	  (2.8	  to	  12)	   3.5	  (1	  to	  6)	   10.5	  (3.5	  to	  22.5)	   7.5	  (4	  to	  21)	  
52	  weeks	   0.5	  (0	  to	  5.8)	   1	  (0	  to	  4.5)	   3	  (0	  to	  8.5)	   3	  (0	  to	  6)	  
Health-­‐related	  quality	  of	  life	  (EQ-­‐5ED)	  d	   	  	   	  	   	  	  
4	  weeks	   0.77	  (0.71	  to	  0.83)	   0.84	  (0.79	  to	  0.89)	   0.91	  (0.87	  to	  0.96)	   0.89	  (0.84	  to	  0.95)	  
26	  weeks	   0.90	  (0.84	  to	  0.96)	   0.93	  (0.89	  to	  0.98)	   0.83	  (0.78	  to	  0.89)	   0.88	  (0.83	  to	  0.94)	  
52	  weeks	   0.94	  (0.89	  to	  0.98)	   0.97	  (0.93	  to	  1.00)	   0.93	  (0.89	  to	  0.98)	   0.92	  (0.85	  to	  1.00)	  
Adverse	  events	  a	   	  	  
Severe	  post-­‐injection	  pain	   1/41,	  2%	  (0	  to	  18%)	   3/41,	  7%	  (2	  to	  25%)	   0/43,	  0%	  (0	  to	  13%)	   0/40,	  0%	  (0	  to	  14%)	  
Pain	  post-­‐injection	  >	  48	  hours	   8/41,	  20%	  (8	  to	  39%)	   5/41,	  12%	  (4	  to	  31%)	   2/43,	  5%	  (1	  to	  21%)	   1/40,	  3%	  (0	  to	  18%)	  
Pain	  post-­‐injection>	  7	  days	   1/41,	  2%	  (0	  to	  18%)	   3/41,	  7%	  (2	  to	  25%)	   1/43,	  2%	  (0	  to	  17%)	   0/40,	  0%	  (0	  to	  14%)	  
Pain	  post-­‐physio	  >	  24	  hours	   NA	   3/41,	  7%	  (2	  to	  25%)	   NA	   2/40	  ,	  5%	  (1	  to	  22%)	  
Pain	  post-­‐physio	  >	  7	  days	   NA	   0/41,	  0%	  (0	  to	  14%)	   NA	   1/40,	  3%	  (0	  to	  18%)	  
Depigmentation	   0/41,	  0%	  (0	  to	  14%)	   0/41,	  0%	  (0	  to	  14%)	   3/43,	  7%	  (2	  to	  24%)	   1/40,	  3%	  (0	  to	  18%)	  
Subcutaneous	  atrophy	   0/41,	  0%	  (0	  to	  14%)	   0/41,	  0%	  (0	  to	  14%)	   2/43,	  5%	  (1	  to	  21%)	   1/40,	  3%	  (0	  to	  18%)	  
Numbness	  of	  hand	   1/41,	  2%	  (0	  to	  18%)	   0/41,	  0%	  (0	  to	  14%)	   1/43,	  2%	  (0	  to	  17%)	   0/40,	  0%	  (0	  to	  14%)	  
Vomiting	   0/41,	  0%	  (0	  to	  14%)	   1/41,	  2%	  (0	  to	  18%)	   0/43,	  0%	  (0	  to	  13%)	   0/40,	  0%	  (0	  to	  14%)	  
Swelling	   0/41,	  0%	  (0	  to	  14%)	   1/41,	  2%	  (0	  to	  18%)	   0/43,	  0%	  (0	  to	  13%)	   0/40,	  0%	  (0	  to	  14%)	  
Skin	  irritation	  from	  taping	   NA	   0/41,	  0%	  (0	  to	  14%)	   NA	   1/40,	  3%	  (0	  to	  18%)	  
Non-­‐protocol	  treatment	  a	   	  	  
Analgesic	  /NSAID	  medication	   16/41,	  39%	  (22	  to	  59%)	   7/41,	  17%	  (7	  to	  36%)	   17/43,	  40%	  (23	  to	  59%)	   9/40,	  23%	  (10	  to	  43%)	  
Medical	  consultation	   6/41,	  15%	  (5	  to	  34%)	   2/41,	  5%	  (1	  to	  21%)	   10/43,	  23%	  (11	  to	  43%)	   5/40,	  13%	  (4	  to	  31%)	  
a Number of events/total sample size, percentage (99% CI).  471	  
b Recurrence defined as complete recovery or much improvement at 4 or 8 weeks, but not 472	  
later. 473	  
c Median (IQR) 474	  
d Mean (99% CI) 475	  
VAS = Visual analogue scale; PRTEE = Patient rated tennis elbow evaluation; EQ-5ED = 476	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